The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
出版年份 2021 全文链接
标题
The impact of FGF19/FGFR4 signaling inhibition in antitumor activity of multi-kinase inhibitors in hepatocellular carcinoma
作者
关键词
-
出版物
Scientific Reports
Volume 11, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-05
DOI
10.1038/s41598-021-84117-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response
- (2019) Stefano Caruso et al. GASTROENTEROLOGY
- First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
- (2019) Richard D Kim et al. Cancer Discovery
- Serum fibroblast growth factor 19 serves as a potential novel biomarker for hepatocellular carcinoma
- (2019) Takahiro Maeda et al. BMC CANCER
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models
- (2018) Masahiro Matsuki et al. Cancer Medicine
- Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression
- (2018) Xiangdong Zhao et al. MOLECULAR CARCINOGENESIS
- Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
- (2017) Lucia Nogova et al. JOURNAL OF CLINICAL ONCOLOGY
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
- (2017) Michael Michael et al. Targeted Oncology
- Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma
- (2015) Victoria Tovar et al. GUT
- Minireview: Roles of Fibroblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases
- (2015) Fangfang Zhang et al. MOLECULAR ENDOCRINOLOGY
- Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets
- (2015) Kornelius Schulze et al. NATURE GENETICS
- Advances in targeted therapies for hepatocellular carcinoma in the genomic era
- (2015) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- Proteogenomic characterization of human colon and rectal cancer
- (2014) Bing Zhang et al. NATURE
- Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
- (2014) Yasushi Totoki et al. NATURE GENETICS
- Exploration of liver cancer genomes
- (2014) Tatsuhiro Shibata et al. Nature Reviews Gastroenterology & Hepatology
- Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer
- (2014) R C Turkington et al. Cell Death & Disease
- FGF Receptors: Cancer Biology and Therapeutics
- (2013) Masaru Katoh et al. MEDICINAL RESEARCH REVIEWS
- Endocrine fibroblast growth factors 15/19 and 21: from feast to famine
- (2012) M. J. Potthoff et al. GENES & DEVELOPMENT
- Targeting FGFR4 Inhibits Hepatocellular Carcinoma in Preclinical Mouse Models
- (2012) Dorothy M. French et al. PLoS One
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- HCC and angiogenesis: possible targets and future directions
- (2011) Andrew X. Zhu et al. Nature Reviews Clinical Oncology
- Molecularly targeted therapy in hepatocellular carcinoma
- (2010) Hung Huynh BIOCHEMICAL PHARMACOLOGY
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
- Present and future possibilities for early diagnosis of hepatocellular carcinoma
- (2010) Piotr Stefaniuk WORLD JOURNAL OF GASTROENTEROLOGY
- Short- and Long-Term Outcomes after Hepatic Resection for Hepatocellular Carcinoma with Concomitant Esophageal Varices in Patients with Cirrhosis
- (2008) Yuichiro Kawano et al. ANNALS OF SURGICAL ONCOLOGY
- The Polycomb Gene Product BMI1 Contributes to the Maintenance of Tumor-Initiating Side Population Cells in Hepatocellular Carcinoma
- (2008) T. Chiba et al. CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation